Vericel (NASDAQ:VCEL) Rating Lowered to Neutral at BTIG Research

Vericel (NASDAQ:VCELGet Rating) was downgraded by equities researchers at BTIG Research from a “buy” rating to a “neutral” rating in a research note issued on Wednesday, MarketBeat Ratings reports.

Other analysts have also recently issued research reports about the company. StockNews.com assumed coverage on Vericel in a research report on Wednesday, October 12th. They set a “sell” rating on the stock. Truist Financial cut Vericel from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Stephens initiated coverage on Vericel in a research report on Thursday, October 13th. They set an “overweight” rating and a $40.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $37.40.

Vericel Trading Up 27.0 %

Shares of NASDAQ VCEL opened at $22.41 on Wednesday. The stock has a market capitalization of $1.06 billion, a PE ratio of -62.25 and a beta of 1.99. The stock’s fifty day simple moving average is $24.51 and its two-hundred day simple moving average is $26.57. Vericel has a 12-month low of $17.30 and a 12-month high of $46.30.

Hedge Funds Weigh In On Vericel

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. raised its stake in Vericel by 3.1% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 12,339 shares of the biotechnology company’s stock worth $311,000 after acquiring an additional 371 shares during the last quarter. Advisors Asset Management Inc. raised its stake in Vericel by 6.7% in the 3rd quarter. Advisors Asset Management Inc. now owns 7,197 shares of the biotechnology company’s stock worth $167,000 after acquiring an additional 452 shares during the last quarter. Teacher Retirement System of Texas raised its stake in Vericel by 7.7% in the 1st quarter. Teacher Retirement System of Texas now owns 8,116 shares of the biotechnology company’s stock worth $310,000 after acquiring an additional 582 shares during the last quarter. Arizona State Retirement System raised its stake in Vericel by 6.1% in the 2nd quarter. Arizona State Retirement System now owns 11,418 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 661 shares during the last quarter. Finally, Prudential Financial Inc. raised its stake in Vericel by 1.5% in the 3rd quarter. Prudential Financial Inc. now owns 50,834 shares of the biotechnology company’s stock worth $1,208,000 after acquiring an additional 768 shares during the last quarter.

Vericel Company Profile

(Get Rating)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.

Read More

Analyst Recommendations for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.